Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGT-274
- Development stage
- Preclinical
- Lead developer
- Regor Therapeutics
- Modality
- Small Molecules
01
Overview
RGT-274 is a preclinical-stage small molecule agonist of the glucagon-like peptide 1 receptor (GLP-1R) being developed by Regor Pharmaceuticals (also known as Regor Therapeutics Group) for the treatment of type 2 diabetes and obesity. As a small molecule GLP-1R agonist, RGT-274 is designed to activate the GLP-1 receptor, which plays a critical role in glucose metabolism and appetite regulation. The compound was discovered using Regor's proprietary rCARD (Computer Accelerated Rational Discovery) platform. While RGT-274 remains in early development, it represents a follow-on program to Regor's more advanced GLP-1R candidate, RGT-075.
02
Targets
Beyond the preview
Go deeper on RGT-274.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGT-274.